Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses.

ABSTRACT: A large number of unwanted adverse events and symptoms reported by patients in clinical trials are not caused by the drug provided, since most of adverse events also occur in corresponding placebo groups. These nocebo effects also play a major role in drug discontinuation in clinical practice, negatively affecting treatment efficacy as well as patient adherence and compliance. Experimental and clinical data document a large interindividual variability in nocebo responses, however, data on psychological, biological or genetic predictors of nocebo responses are lacking. Thus, with an established paradigm of behaviorally conditioned immunosuppressive effects we analyzed possible genetic predictors for nocebo responses. We focused on the genetic polymorphisms in the catechol-O-methyltransferas

SUBMITTER: Wendt L 

PROVIDER: S-EPMC4164653 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature